Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
NEW YORK, Jan. 05, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Alexion Pharmaceuticals, Inc. securities (NASDAQ:ALXN) from February 10, 2014 through November 9, 2016, inclusive (the “Class Period”) of the important January 17, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Alexion investors under the federal securities laws.
To join the Alexion class action, go to http://rosenlegal.com/cases-991.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Alexion employed improper sales practices with respect to Soliris; (2) consequently, Alexion’s revenues from Soliris sales were unlikely to be sustainable; and (3) as a result, Alexion’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-991.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
